Evidence map›Paper›PMID 33810169›Full record

ArticleCancers2021

Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Daniela Damasceno, Julia Almeida, Cristina Teodosio, Luzalba Sanoja-Flores, Andrea Mayado, Alba Pérez-Pons, Noemi Puig, Paula Arana, Bruno Paiva, Fernando Solano and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Monoclonal Gammopathies in Africa.Clinical lymphoma, myeloma & leukemia · 2025
    Review
  3. Article
  4. T-lymphocytes suppression by CD14Journal of translational medicine · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Origin of Osteoclasts: Osteoclast Precursor Cells.Journal of bone metabolism · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Daniela DamascenoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-9192-430X
Julia AlmeidaTranslational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0003-3124-8917
Cristina TeodosioLeiden University Medical Center, Department of Immunology, 2333 ZA Leiden, The Netherlands.
Luzalba Sanoja-FloresBiomedical Research Networking Centre Consortium of Oncology (CIBERONC) (CB16/12/00400), Instituto Carlos III, 28029 Madrid, Spain.
Andrea MayadoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Alba Pérez-PonsTranslational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-5805-1391
Noemi PuigBiomedical Research Networking Centre Consortium of Oncology (CIBERONC) (CB16/12/00400), Instituto Carlos III, 28029 Madrid, Spain.
Paula AranaRegulation of the Immune System Group, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Plaza de Cruces 12, 48903 Barakaldo, Spain.
Bruno PaivaBiomedical Research Networking Centre Consortium of Oncology (CIBERONC) (CB16/12/00400), Instituto Carlos III, 28029 Madrid, Spain.
Fernando SolanoHematology Service, Hospital Nuestra Señora del Prado, Talavera de la Reina, 45600 Toledo, Spain.
Alfonso RomeroPrimary Health Care Center "Miguel Armijo", Primary Health Care of Salamanca, Conserjería de Sanidad de Castilla y León (SACYL), 37007 Salamanca, Spain.
Sergio MatarrazTranslational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Wouter B L van den BosscheLeiden University Medical Center, Department of Immunology, 2333 ZA Leiden, The Netherlands.
Juan Flores-MonteroTranslational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-1119-4387
Brian DurieCentro del Cáncer Cedars-Sinai Samuel Oschin, Los Angeles, CA 90048, USA.
Jacques J M van DongenLeiden University Medical Center, Department of Immunology, 2333 ZA Leiden, The Netherlands.
Alberto OrfaoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-0007-7230
Universidad de Salamanca · ESLeiden University Medical Center · NLBioCruces Health research Institute · ESCedars-Sinai Medical Center · USCentre for Biomedical Network Research on Rare Diseases · ESConsejo Superior de Investigaciones Científicas · ESHospital General Nuestra Señora del Prado · ESJunta de Castilla y León · ES

Funding

Centro de Investigación Biomédica en Red de Cáncer CB16/12/00233Centro de Investigación Biomédica en Red de Cáncer CB16/12/00369Centro de Investigación Biomédica en Red de Cáncer CB16/12/00400H2020 European Research Council ERC-2015-AdG 695655International Myeloma Foundation IMF13/ IMF16
6 · The paper itself

Abstract

backgroundMonocyte/macrophages have been shown to be altered in monoclonal gammopathy of undetermined significance (MGUS), smoldering (SMM) and active multiple myeloma (MM), with an impact on the disruption of the homeostasis of the normal bone marrow (BM) microenvironment.

methodsWe investigated the distribution of different subsets of monocytes (Mo) in blood and BM of newly-diagnosed untreated MGUS (

resultsOur results showed normal production of monocyte precursors and classical Mo (cMo) in MGUS, while decreased in SMM and MM (

conclusionsThese results provide new insight into the pathogenesis of plasma cell neoplasms and the potential role of FcεRI

Indexed as

bone markersFcεRI monocytesimmunosenescenceinflammatory cytokinesMGUSmonocytesmultiple myelomaplasma cell neoplasmstumor microenvironment

Identifiers

PMID33810169
PMCPMC8004952
OpenAlexW3138416708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.